Mid-day market update: Gold drops over 2%, Leap Therapeutics shares jump
|Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, dropping 0.79% to 4,445.34.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 41,539,100 cases with around 666,620 deaths. India confirmed a total of at least 33,347,320 cases and 443,920 deaths, while Brazil reported over 21,034,610 COVID-19 cases with 588,590 deaths. In total, there were at least 226,445,290 cases of COVID-19 worldwide with more than 4,661,150 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Consumer discretionary shares slipped by just 0.1% on Thursday. Meanwhile, top gainers in the sector included Tuesday Morning Corporation TUEM +undefined% (Get Free Alerts for TUEM), up 23% and Vinco Ventures, Inc. BBIG +undefined% (Get Free Alerts for BBIG) up 9%.
In trading on Thursday, materials shares tumbled 1.7%.
Top Headline
US retail sales increased 0.7% in August of 2021, following a revised 1.8% decline in July. Analysts were expecting for a 0.8% decline in retail trade.
Equities Trading UP
Leap Therapeutics, Inc. LPTX +undefined% shares shot up 23% to $2.3650 after the company announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene’s tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ).
Shares of Tuesday Morning Corporation TUEM +undefined% (Get Free Alerts for TUEM) got a boost, shooting 24% to $2.1450 after a SEC filing showed CEO Fred Hand purchased 511,387 shares of the company's common stock at an average price of $1.76.
TMC the metals company Inc. TMC +undefined% shares were also up, gaining 26% to $12.58 amid increased retail investor interest in the stock on social media.
Equities Trading DOWN
Silverback Therapeutics, Inc. SBTX +24.06% shares tumbled 28% to $11.72. The company presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with Merck & Co's Keytruda in patients with advanced or metastatic HER2-expressing or amplified solid tumors.
Shares of Aerie Pharmaceuticals, Inc. AERI +23.79% were down 28% to $11.29 after the company announced topline results of its Phase 2b COMET-1 study evaluating AR-15512 (TRPM8 Agonist) ophthalmic solution for dry eye disease. The company said that the study failed to achieve statistical significance at pre-determined primary endpoints at Day 28.
MacroGenics, Inc. MGNX +26.66% was down, falling 24% to $20.84 as the company disclosed results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab.
Commodities
In commodity news, oil traded down 1% to $71.87, while gold traded down 2.3% to $1,752.80.
Silver traded down 4.8% Thursday to $22.65 while copper fell 2.7% to $4.2890.
Euro zone
European shares were higher today. The eurozone’s STOXX 600 gained 0.6%, the Spanish Ibex Index rose 1.18% and the German DAX 30 gained 0.49%. Meanwhile, the London’s FTSE 100 rose 0.31%, French CAC 40 climbed 0.81% and Italy’s FTSE MIB jumped 0.99%.
The Eurozone trade surplus shrank to EUR 20.7 billion in July from EUR 26.8 billion in the year-ago period, while passenger car registrations in the European Union dropped 19.1% year-over-year to 623 thousand units in August. Italy’s trade surplus narrowed to EUR 8.762 billion in July from EUR 9.689 billion in the year-ago month.
Economics
US initial jobless claims increased to 332 thousand in the week ending September 11 versus a reading of 312 thousand in the previous week.
The Philadelphia Fed manufacturing index climbed to 30.7 in September from 19.4 in August.
Retail sales increased 0.7% in August of 2021, following a revised 1.8% decline in July.
US business inventories rose 0.5% for July.
US natural-gas supplies surged 83 billion cubic feet last week, the Energy Information Administration said.
The Treasury International Capital report for July will be released at 4:00 p.m. ET.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.